Oct 28 (Reuters) - Theratechnologies Inc TH.TO
* Theratechnologies -phase iii study primary endpoint results show ibalizumab significantly reduced viral load in patients with multi-drug resistant hiv-1
* Announced additional results related to primary endpoint of ibalizumab phase iii pivotal study, tmb-301
* Theratechnologies-Topline results of safety,secondary efficacy endpoints for 24-week treatment period for ibalizumab will be announced in coming weeks Source text for Eikon: ID:nCCN4vrtfg Further company coverage: TH.TO